Bringing your ideas to life
In support of implantable technologies as diverse as cardiovascular devices, orthopedic implants, tissue regeneration scaffolds, and wound management systems, we offer you a proven family of resorbable polymers – supported by years of expertise across everything from contract manufacturing to custom synthesis.
When it comes to biomedical and resorbable polymers, our track record stretches back to the 1960s.
Today, our state-of-the-art GMP production, research and QA/QC facilities make us one of the most reliable large-scale (yet independent) partners to the industry.
Our PURASORB® family of resorbable polymers can be produced in batch sizes of 5kg up to over 100kg – across a broad range of different specifications. Our R&D laboratory includes a 2kg scale pilot facility, as well as a variety of equipment dedicated to the development and support of polymer compositions.
But our expertise isn’t limited to manufacturing: We also provide extended analytical services and analytical method development and validation.
Quality resorbable polymers for biomedical
We adhere strictly to all ICHQ7 guideline-based quality system, which form the basis of our processes and analytical methods.
This includes a Certificate of Analysis for every batch we produce, showing the analytical data determined in our quality control laboratory (with additional analytical data available on request).
We are ISO-9001: 2008 and ISO-14001: 2004 certified and all our polymers and monomers are covered with a Device Master File (MAF 1346) and a Drug Master File (DMF 21817) filed at the FDA.
Most importantly, we allow customers to see this for themselves: They audit our facilities on a regular basis.
We adhere strictly to all ICHQ7 guideline-based quality system and our processes and analytical methods are validated accordingly
Product not available in your region
This product is not available in the selected region.
If you want this product in your region, or find a suitable alternative, please contact us,
Corbion proposes re-appointment CFO Eddy Van Rhede van der Kloot
Corbion's Supervisory Board proposes to re-appoint CFO Eddy van Rhede van der Kloot for a
(S)-Lactic acid approved for use as an active substance in biocidal products under the BPR (EU)
The European Commission has approved (S)-lactic acid for use as active substance in biocidal products
Corbion Strategy Update: Creating Sustainable Growth
During its Capital Markets Day for analysts and investors in Amsterdam today, Corbion management will